Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary

Emergent BioSolutions reported Q3 2026 revenue of $110M, a 52.4% YoY decline, and a net loss of $32.7M, compared to a profit of $51.2M a year earlier. Nine-month revenue fell 16% to $500.4M, driven by lower NARCAN sales and declines in medical countermeasure products. The company reduced its workforce by 90 employees in August to cut costs.

Original reporting
Published Nov 3, 2026, 11:01 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 3, 2026, 11:10 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
Emergent BioSolutions 2026: Revenue $110M, EPS ($0.64) — 10-Q Summary — source image
Decision brief

The 30-second read

$EBSBearishMed
01

Why it matters

The earnings miss could trigger short‑term sell pressure, but restructuring and future product sales may provide upside later.

02

Market read

EBS earnings are a primary catalyst for its stock and may influence the broader biotech sector.

03

What to watch

Potential cost savings from the recent restructuring and upcoming product launches may mitigate the short‑term downside.

Relevance 8/10Novelty 8/10Timing: after-hours release

Background

Emergent BioSolutions filed its 10‑Q for Q3 2026, showing a sharp decline in NARCAN and medical countermeasure sales.

Company-level read

Ticker impact

$EBSBearishHigh confidence
Context

Emergent BioSolutions reported Q3 2026 revenue of $110M and a net loss of $32.7M, a 52% revenue drop YoY.

Expected impact

downward pressure as the market prices in the earnings miss and loss

Evidence & confidence

The earnings release reveals a 52% revenue decline and a $32.7M loss, which are material negative catalysts.

Market effects

The biotech/biopharma sector may see broader pressure as a peer reports weaker countermeasure sales.

U.S. biotech stocks could see modest pullback in the afternoon session.

Limited; the impact is primarily confined to U.S. listed biotech equities.

Counterpoint

If the market overreacts to the loss, a bounce could occur on the upcoming pipeline milestones.

Key entities

  • Emergent BioSolutions Inc.

    U.S. biotech firm focused on medical countermeasures.

Related articles

$EBSMedAI 8/10

Emergent BioSolutions Inc (EBS) (Q3 2026) Earnings Call Highlights: Revenue Timing Weighs

Emergent BioSolutions reported Q3 2026 revenue of $110M, down from $231M in Q3 2025 due to MCM delivery timing. Adjusted EBITDA was -$5M, with adjusted gross margin at 28%. Full-year 2026 revenue guidance was updated to $600M-$645M. The company faces competitive pricing pressure in the naloxone market and expects MCM revenues to decline. CFO Richard Lindahl is retiring, and net leverage remained stable at 2.4 times.

$EBSMed

Emergent BioSolutions (EBS) Q3 2026 Earnings Call Transcript

Emergent BioSolutions reported Q3 2026 revenue of $110M, within guidance, bringing YTD revenue to $500M. Adjusted EBITDA reached $128M (25% margin), with $122M in operating cash flow. The company highlighted progress in its transformation plan, including contract modifications and international sales. CFO Rich Lindahl announced his retirement, with Frank Vargo assuming the role in 2027. The company also discussed its role in biodefense and AI partnerships for clinical development.

$EBSMed

Emergent Biosolutions Q3 Earnings Call Highlights

Emergent Biosolutions reported Q3 cash of $176M, reduced gross debt by $179M YoY, and repurchased $75M in bonds. MCM revenue was $59M, with international sales contributing $72M. Naloxone market faced competition. 2026 revenue guidance updated to $600M-$645M. CFO to retire, interim replacement named. (EBS)

$EBSMed

EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS

Emergent BioSolutions Inc. (EBS) filed an SEC Form 8-K — Results of Operations and Financial Condition. EMERGENT BIOSOLUTIONS REPORTS THIRD QUARTER 2026 FINANCIAL RESULTS • Third Quarter 2026 Total Revenues of $110.0 million • Third Quarter 2026 Net Loss of $32.7 million and Net Loss Margin was (30)% • Third Quarter 2026 Adjusted Net Loss of $18.7 million • Third Quarter 2026 Gross